Cover Image
市場調查報告書

吸煙成癮症:開發中產品分析

Smoking Addiction - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363109
出版日期 內容資訊 英文 107 Pages
訂單完成後即時交付
價格
Back to Top
吸煙成癮症:開發中產品分析 Smoking Addiction - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 107 Pages
簡介

本報告提供吸煙成癮症治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

吸煙成癮症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

吸煙成癮症:企業開發中的治療藥

吸煙成癮症:大學/機關研究中的治療藥

吸煙成癮症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

吸煙成癮症:企業開發中的產品

吸煙成癮症:大學/機關研究中的產品

吸煙成癮症治療藥的開發企業

  • Aradigm Corporation
  • Arena Pharmaceuticals, Inc.
  • Astraea Therapeutics, LLC
  • Bioprojet SCR
  • Cerecor Inc.
  • CoMentis, Inc.
  • Embera NeuroTherapeutics, Inc.
  • Euthymics Bioscience, Inc.
  • Invion Limited
  • Johnson & Johnson
  • Marinus Pharmaceuticals, Inc.
  • NAL Pharmaceuticals Ltd.
  • Pfizer Inc.
  • Selecta Biosciences, Inc.
  • Zynerba Pharmaceuticals, Inc.

吸煙成癮症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

吸煙成癮症:暫停中的計劃

吸煙成癮症:中止開發的產品

吸煙成癮症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8176IDB

Summary

Global Markets Direct's, 'Smoking Addiction - Pipeline Review, H1 2016', provides an overview of the Smoking Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Smoking Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Smoking Addiction
  • The report reviews pipeline therapeutics for Smoking Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Smoking Addiction therapeutics and enlists all their major and minor projects
  • The report assesses Smoking Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Smoking Addiction

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Smoking Addiction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Smoking Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Smoking Addiction Overview
  • Therapeutics Development
    • Pipeline Products for Smoking Addiction - Overview
    • Pipeline Products for Smoking Addiction - Comparative Analysis
  • Smoking Addiction - Therapeutics under Development by Companies
  • Smoking Addiction - Therapeutics under Investigation by Universities/Institutes
  • Smoking Addiction - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Smoking Addiction - Products under Development by Companies
  • Smoking Addiction - Products under Investigation by Universities/Institutes
  • Smoking Addiction - Companies Involved in Therapeutics Development
    • Aradigm Corporation
    • Arena Pharmaceuticals, Inc.
    • Astraea Therapeutics, LLC
    • Bioprojet SCR
    • Cerecor Inc.
    • CoMentis, Inc.
    • Embera NeuroTherapeutics, Inc.
    • Euthymics Bioscience, Inc.
    • Invion Limited
    • Johnson & Johnson
    • Marinus Pharmaceuticals, Inc.
    • NAL Pharmaceuticals Ltd.
    • Pfizer Inc.
    • Selecta Biosciences, Inc.
    • Zynerba Pharmaceuticals, Inc.
  • Smoking Addiction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (metyrapone + oxazepam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amitifadine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Anatabine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BP-1.4979 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CERC-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ganaxolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GTS-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-39393406 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lorcaserin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nadolol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NFL-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NIC7-DT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nicotine bitartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nicotine bitartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nicotine Vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-05402536 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06413367 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEL-070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Smoking Cessation and Appetite Suppression - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URB-694 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Smoking Addiction - Dormant Projects
  • Smoking Addiction - Discontinued Products
  • Smoking Addiction - Product Development Milestones
    • Featured News & Press Releases
      • Apr 11, 2016: Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health
      • Feb 02, 2016: Cerecor Announces Initiation of Phase 2 Clinical Trial With CERC-501 for Smoking Cessation
      • Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis
      • Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation
      • Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation
      • Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation
      • Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation
      • Nov 04, 2014: Lorcaserin Meets Primary Endpoint And Confirms Proof-Of-Concept As Potential Aid For Smoking Cessation In Investigational Phase II Clinical Study
      • Nov 03, 2014: Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation
      • Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform
      • May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ (lorcaserin HCl) CIV by 50%
      • Jan 29, 2014: FDA clears path for "Smoking Cessation" clinical trial of INV102 (nadolol)
      • Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial
      • Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL
      • Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Smoking Addiction, H1 2016
  • Number of Products under Development for Smoking Addiction - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Smoking Addiction - Pipeline by Aradigm Corporation, H1 2016
  • Smoking Addiction - Pipeline by Arena Pharmaceuticals, Inc., H1 2016
  • Smoking Addiction - Pipeline by Astraea Therapeutics, LLC, H1 2016
  • Smoking Addiction - Pipeline by Bioprojet SCR, H1 2016
  • Smoking Addiction - Pipeline by Cerecor Inc., H1 2016
  • Smoking Addiction - Pipeline by CoMentis, Inc., H1 2016
  • Smoking Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H1 2016
  • Smoking Addiction - Pipeline by Euthymics Bioscience, Inc., H1 2016
  • Smoking Addiction - Pipeline by Invion Limited, H1 2016
  • Smoking Addiction - Pipeline by Johnson & Johnson, H1 2016
  • Smoking Addiction - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016
  • Smoking Addiction - Pipeline by NAL Pharmaceuticals Ltd., H1 2016
  • Smoking Addiction - Pipeline by Pfizer Inc., H1 2016
  • Smoking Addiction - Pipeline by Selecta Biosciences, Inc., H1 2016
  • Smoking Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Smoking Addiction - Dormant Projects, H1 2016
  • Smoking Addiction - Dormant Projects (Contd..1), H1 2016
  • Smoking Addiction - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Smoking Addiction, H1 2016
  • Number of Products under Development for Smoking Addiction - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top